Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like Research reveals Medicare’s inadequate payments for lifesaving stroke procedures July 25, 2024 Hearing aids may help older adults combat social isolation May 12, 2025 Community-led intervention curbs childhood obesity and boosts quality of life November 12, 2024